L & C BIO
L&C BIO Inc. is a South Korean regenerative medicine company developing and manufacturing human-derived tissue products, medical devices, and aesthetic regenerative solutions under its proprietary AlloClean® technology, selling to hospitals, surgical centers, and dermatology clinics in Korea, China, Japan, and Southeast Asia.
- Company typePublic
- Founded2015
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What L & C BIO does
L&C BIO Inc. is a South Korea-based regenerative medicine and biotechnology company that develops, manufactures, and sells human-derived tissue products, medical devices, and aesthetic regenerative solutions for hospitals, surgical centers, and dermatology clinics. The company's product portfolio is organized around its proprietary AlloClean® acellular dermal matrix processing technology, which removes cells and immunogenic factors while preserving ECM structural integrity, and spans skin (MegaDerm family, Re2O skin boosters), bone (MegaBone, MegaDBM), cartilage (MegaCarti, MegaCartilage), tendon/ligament, nerve (MegaNerve Prime), fascia, anti-adhesion (MegaShield), wound healing, and AI-powered diagnostic devices (Luskin X).
The business operates on a B2B enterprise sales model with quote-based pricing and multi-year contracts, with revenue generated through one-time sales of tissue grafts and medical devices to medical institutions. Distribution is hybrid: direct enterprise field sales to Korean hospitals and clinics, local manufacturing through the L&C China joint venture (with CICC) for the Chinese market, and distributor relationships for Japan, Southeast Asia, and emerging markets. The company holds over 50% market share in the Korean human tissue product category and has secured first-mover foreign-enterprise NMPA approval in China. Geographic footprint covers South Korea, China, Japan, Myanmar, Singapore, and other Southeast Asian markets, with a strong K-Medical tourism positioning around the Re2O regenerative aesthetic franchise.
Manufacturing is vertically integrated across a human tissue plant in Seongnam (headquarters), a pharmaceutical plant in Anseong, R&D and sales centers in Seoul and Busan, and a 24,000 sqm Kunshan, China facility. The company went public on KOSDAQ in 2018, is led by CEO Lee Hwan-cheol, and is supported by a portfolio of 16+ granted patents covering processing methods, compositions, and 3D bioprinting bio-inks.
L & C BIO firmographics
Firmographics- Name
- L & C BIO
- Legal name
- L&C BIO Inc.
- Website
- https://lncbio.co.kr
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- L&C BIO Inc. is a South Korean regenerative medicine company developing and manufacturing human-derived tissue products, medical devices, and aesthetic regenerative solutions under its proprietary AlloClean® technology, selling to hospitals, surgical centers, and dermatology clinics in Korea, China, Japan, and Southeast Asia.
- Ownership category
- akta.pro rank
L & C BIO industry classification
Industry- Product category
- Regenerative Medicine / Human Tissue Products
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where L & C BIO is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices7 records
Markets served
L & C BIO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Human Tissue Products: Sale of processed human tissue products including MegaDerm (skin grafts), MegaFill (dermal fillers), MegaBone (bone tissue), MegaCartilage, MegaTendon, MegaNerve for reconstructive and regenerative surgeries.
- Medical Devices: Sale of medical devices including MegaCarti (cartilage repair), MegaShield (anti-adhesion), MegaDBM (bone graft materials), MegaCure (wound protection) for surgical applications.
- Aesthetic/Regenerative Products: Re2O and Re2O Fine ECM skin boosters sold to dermatology and aesthetic clinics for cosmetic procedures, medical tourism, and anti-aging treatments.
- China Local Manufacturing: Local production and sales in China through L&C China subsidiary, targeting Chinese domestic market with products like MegaDerm Plus following NMPA approval.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise/B2B pricing for medical institutions |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
L & C BIO product offering
Product offeringCore offering
L&C Bio manufactures and sells processed human tissue products (skin, bone, cartilage, tendon, nerve, fascia grafts and ECM skin boosters) and medical devices (anti-adhesion barriers, bone graft materials, wound dressings, cryosurgery and diagnostic instruments) for reconstructive surgery, orthopedic repair, and regenerative aesthetic procedures. The company operates GMP manufacturing facilities in South Korea and China (Kunshan JV) and holds proprietary AlloClean® acellular dermal matrix processing technology.
Product overview
L&C Bio is a regenerative medicine and biotechnology company specializing in human tissue products and medical devices. The company operates with a platform-based portfolio structure organized around its proprietary AlloClean technology for processing human-derived tissues. Core product categories include: (1) Human Tissue Products for transplantation and reconstruction including skin (MegaDerm family, Re2O skin boosters, MegaFill filler), bone (MegaBone), cartilage (MegaCartilage, MegaCarti medical device), tendon/ligament (MegaTendon), nerve (MegaNerve Prime), and fascia (MegaSheet); (2) Medical Devices including bone grafts (MegaDBM, MegaBone Oss), wound care (MegaShield, MegaCure, MegaHeal), and surgical instruments (CryoPen, Fluobeam); (3) AI-powered Devices including Luskin X 3D skin diagnostic system. The company serves medical tourism, aesthetic medicine, and surgical reconstruction markets primarily in Korea, China, Japan, and Southeast Asia.
Differentiator
Problem solved
Functional benefit
Brands
- Re2O: Regenerative skin enhancement product made from micro particulate human acellular dermal matrix (hADM), composed of collagen, elastin and hyaluronic acid ECM components
- MegaDerm
- MegaCarti
- MegaShield
- MegaDBM
- MegaBone
- AlloClean Technology
Products and services
- Re2O Skin enhancer made from micro-particle human acellular dermal matrix (hADM), composed of essential ECM components including collagens, elastin, proteins, and hyaluronic acid. Used for aesthetic and regenerative medicine procedures by dermatology and aesthetic clinics.
- Re2O Fine Finer particle version of Re2O for more delicate treatment areas, same ECM-based composition as Re2O for aesthetic and regenerative medicine procedures.
- MegaDerm Human-derived acellular dermal matrix processed using AlloClean technology. Used in skin transplantation and soft-tissue reconstruction; converts to autologous tissue after transplantation. For hospitals and surgical centers.
- MegaDerm HD Pre-hydrated MegaDerm with approximately 40% improved flexibility compared to freeze-dried type. Can be used directly without additional hydration process. For surgical centers and hospitals.
- MegaDerm Plus
Quantifiable outcome
- Re2O became leading K-Medical tourism procedure within one year of launch
- +1 more outcomes
Companies that use L & C BIO
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
L & C BIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
L & C BIO partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- L&C China (L&C BIO Science Technology)coreJoint venture subsidiary established in Kunshan, Jiangsu province for local manufacturing of human tissue products. Total investment of 1.5 billion CNY with 24,000 sqm manufacturing facility.
- Kunshan City Government / Luojia GovernmentcoreKunshan city and Luojia town governments provided strong support for L&C Bio's entry as the first company in the Sino-Korean Medical/Aesthetic/Bio Industry Park. Government committed full support for regulatory approvals and business operations.
- Myanmar medical professionals and distributorsminorL&C Bio conducted Re2O webinars for Myanmar medical professionals and participated in MSAAH (Myanmar Society of Aesthetic Anti-Aging and Healthcare) conference to expand market presence.
- Korean Medical Data Association (대한국민자료협회)minorStrategic cooperation established during Kunshan Luojia government visit to Korea, aimed at facilitating Korean medical and bio companies' entry into the Chinese market through the industry park.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
L & C BIO competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Diversified medical device incumbent covering spine, orthopedics and surgical solutions; tangential competitor to L&C's orthopedic and reconstructive surgery offerings.
- Integra LifeSciences: Broadly diversified medical device and regenerative technologies company with Integra Dermal Regeneration Template and wound care portfolio — overlapping with MegaDerm/MegaCure/MegaHeal but from a larger established US player.
- Stryker: Global orthopedic medical device giant whose orthobiologics and surgical segments overlap with MegaBone, MegaDBM and MegaCarti; broader portfolio but relevant competition in regenerative orthopedics.
Direct peers
- MiMedx Group: US-based pioneer of dehydrated human amnion/chorion membrane and other skin-substitute allografts; directly overlaps with L&C Bio's MegaDerm/Re2O acellular dermal matrix franchise in wound healing and regenerative aesthetics.
- AlloSource: Non-profit tissue bank providing allograft skin, bone, tendon and cartilage products — directly comparable to L&C Bio's broad human tissue allograft portfolio anchored by AlloClean.
- MTF Biologics: Tissue processor offering skin, bone, cartilage, tendon and wound care allografts; competes head-to-head with the MegaDerm and MegaCartilage product lines in orthopedic and reconstructive surgery.
- LifeNet Health: Non-profit regenerative medicine company producing dermal matrices, bone grafts and cardiovascular allografts; direct peer in the acellular dermal matrix and bone graft categories.
- Tissue Regenix: UK-based regenerative medicine company commercializing decellularized scaffolds (dCELL) for skin, bone and cardiac applications — direct technology overlap with AlloClean.
Regional players
- CGBio: Korean bone graft substitute and regenerative medicine peer; competes regionally with L&C Bio's bone and cartilage products in the Korean hospital channel.
Emerging players
- Humeca: Dutch skin graft and burn care specialist (meek, meshed grafts); smaller but adjacent peer in the skin substitute and wound healing space where MegaDerm and MegaHeal compete.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
L & C BIO social profiles
Digital presenceL & C BIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
L & C BIO leadership team
Management profileNumber of profiles
Profiles3 records
L & C BIO subsidiaries and ownership
Company hierarchySubsidiaries3 records
L & C BIO funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
L & C BIO M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about L & C BIO
What does L & C BIO do?
L&C Bio manufactures and sells processed human tissue products (skin, bone, cartilage, tendon, nerve, fascia grafts and ECM skin boosters) and medical devices (anti-adhesion barriers, bone graft materials, wound dressings, cryosurgery and diagnostic instruments) for reconstructive surgery, orthopedic repair, and regenerative aesthetic procedures. The company operates GMP manufacturing facilities in South Korea and China (Kunshan JV) and holds proprietary AlloClean® acellular dermal matrix processing technology.
Is L & C BIO a public or private company?
L & C BIO is a public company. It is classified as public and is currently operating.
When was L & C BIO founded?
L & C BIO was founded in 2015. It employs 51 to 100 people.
Where is L & C BIO based?
L & C BIO is headquartered in Seongnam, South Korea, in the Asia region.
How does L & C BIO make money?
Four revenue lines are on record. Human Tissue Products are the primary driver. The others are medical Devices, aesthetic/Regenerative Products and china Local Manufacturing.
Who are L & C BIO's main competitors?
Broad incumbents on record are Medtronic, Integra LifeSciences and Stryker. Direct peers are MiMedx Group, AlloSource, MTF Biologics, LifeNet Health and Tissue Regenix. CGBio is listed as a regional player. Humeca is listed as an emerging player.
Does L & C BIO have an API?
No public API is recorded for L & C BIO.
What industry is L & C BIO in?
L & C BIO's product category is Regenerative Medicine / Human Tissue Products. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.